ZOLEDRONIC ACID injection, solution, concentrate

Country: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

Zoledronic Acid (UNII: 6XC1PAD3KF) (Zoledronic Acid Anhydrous - UNII:70HZ18PH24)

Disponibbli minn:

Akorn

INN (Isem Internazzjonali):

Zoledronic Acid

Kompożizzjoni:

Zoledronic Acid Anhydrous 4 mg in 5 mL

Rotta amministrattiva:

INTRAVENOUS

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL= Ca in mg/dL + 0.8 (4.0 g/dL – patient albumin [g/dL]). Zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. Limitations of Use The safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. Hypersensitivity to Zoledronic Acid or Any Components of Zoledronic Acid Injection Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see Advers

Sommarju tal-prodott:

Zoledronic Acid Injection, 4 mg/5 mL (0.8 mg/mL) single-dose vial for dilution prior to intravenous infusion is available in Storage: Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Discard unused portion.

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

ZOLEDRONIC ACID- ZOLEDRONIC ACID INJECTION, SOLUTION, CONCENTRATE
AKORN
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ZOLEDRONIC ACID
INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
ZOLEDRONIC ACID
INJECTION.
ZOLEDRONIC ACID INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 2001
INDICATIONS AND USAGE
Zoledronic acid injection is a bisphosphonate indicated for the
treatment of:
Hypercalcemia of malignancy. (1.1)
Patients with multiple myeloma and patients with documented bone
metastases from solid tumors, in
conjunction with standard antineoplastic therapy. Prostate cancer
should have progressed after
treatment with at least one hormonal therapy. (1.2)
Limitations of use: The safety and efficacy of zoledronic acid
injection has not been established for use in
hyperparathyroidism or non-tumor-related hypercalcemia.
DOSAGE AND ADMINISTRATION
Hypercalcemia of malignancy (2.1)
4 mg as a single-use intravenous infusion over no less than 15
minutes.
4 mg as retreatment after a minimum of 7 days.
Multiple myeloma and bone metastasis from solid tumors. (2.2)
4 mg as a single-use intravenous infusion over no less than 15 minutes
every 3 to 4 weeks for patients
with creatinine clearance of greater than 60 mL/min.
Reduce the dose for patients with renal impairment.
Coadminister oral calcium supplements of 500 mg and a multiple vitamin
containing 400 international
units of vitamin D daily.
Administer through a separate vented infusion line and do not allow to
come in contact with any calcium or
divalent cation-containing solutions. (2.3)
DOSAGE FORMS AND STRENGTHS
Injection: 4 mg/5 mL (0.8 mg/mL) single-dose vial for dilution prior
to intravenous infusion (3)
CONTRAINDICATIONS
Hypersensitivity to any component of zoledronic acid injection (4)
WARNINGS AND PRECAUTIONS
Patients being treated with zoledronic acid injection should not be
treated with Reclast
. (5.1)
Adequately rehydrate patients with hypercalcemia of malignancy prior
t